FY2025 EPS Estimates for YMAB Lowered by Cantor Fitzgerald

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for Y-mAbs Therapeutics in a research report issued on Wednesday, March 5th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings of ($0.92) per share for the year, down from their previous estimate of ($0.67). The consensus estimate for Y-mAbs Therapeutics' current full-year earnings is ($0.65) per share.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). The business had revenue of $26.50 million for the quarter, compared to the consensus estimate of $26.70 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same period in the previous year, the company earned ($0.02) EPS.

Several other equities analysts have also recently issued reports on YMAB. Truist Financial lowered their price objective on Y-mAbs Therapeutics from $21.00 to $18.00 and set a "buy" rating on the stock in a research report on Wednesday, March 5th. Oppenheimer assumed coverage on shares of Y-mAbs Therapeutics in a research report on Monday, November 18th. They set an "outperform" rating and a $23.00 price objective for the company. Brookline Capital Management started coverage on shares of Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a "buy" rating and a $17.00 target price for the company. HC Wainwright reissued a "buy" rating and set a $22.00 price target on shares of Y-mAbs Therapeutics in a report on Monday, January 13th. Finally, Morgan Stanley lowered their target price on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Y-mAbs Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $19.30.

Remove Ads

Y-mAbs Therapeutics Stock Performance

Shares of Y-mAbs Therapeutics stock traded up $0.18 during midday trading on Friday, hitting $4.94. The company had a trading volume of 338,078 shares, compared to its average volume of 467,358. The company has a 50 day moving average of $6.22 and a 200 day moving average of $10.38. Y-mAbs Therapeutics has a 52-week low of $4.25 and a 52-week high of $17.78. The stock has a market capitalization of $223.38 million, a P/E ratio of -9.15 and a beta of 0.65.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Large investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Y-mAbs Therapeutics during the 3rd quarter worth approximately $44,000. KLP Kapitalforvaltning AS acquired a new position in Y-mAbs Therapeutics in the 4th quarter worth approximately $46,000. Intech Investment Management LLC purchased a new position in shares of Y-mAbs Therapeutics during the third quarter worth $133,000. ProShare Advisors LLC acquired a new position in shares of Y-mAbs Therapeutics in the 4th quarter valued at about $99,000. Finally, Empire Financial Management Company LLC acquired a new position in Y-mAbs Therapeutics in the third quarter valued at approximately $210,000. Institutional investors own 70.85% of the company's stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.